Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T14:53:24.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis

Published online by Cambridge University Press:  13 June 2019

Gurpreet Kaur Open the ORCID record for Gurpreet Kaur [Opens in a new window] ,
Kalpana Chauhan  and
Sukhbir Kaur
Gurpreet Kaur
Affiliation:
Department of Zoology, Panjab University, Chandigarh, India
Kalpana Chauhan
Affiliation:
Department of Zoology, Panjab University, Chandigarh, India
Sukhbir Kaur*
Affiliation:
Department of Zoology, Panjab University, Chandigarh, India
*
Author for correspondence: Sukhbir Kaur, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The available chemotherapeutics for the cure of visceral leishmaniasis (VL) are linked with many detrimental effects. Moreover, VL is associated with the suppression of protective Th1 immune response of the host and induction of disease exaggerating Th2 immune response. Therefore, there is an urgent requirement of therapeutics which can augment the immune status of the host to cure this disease. In the current investigation, the antileishmanial potential of lupeol was monitored in vitro and in vivo in inbred BALB/c mice against Leishmania donovani. Lupeol showed potent antipromastigote activity via arresting parasites at sub G0/G1 phase in vitro. Lupeol significantly decreased the splenic parasite burden by inducing strong delayed-type hypersensitivity responses in contrary to untreated infected animals. The therapeutic efficacy of lupeol was observed to be similar to the reference drug, AmB. Treatment of infected animals with lupeol depicted enhanced levels of T cells and Th1 cytokines in contrast to only infected controls. Further lupeol treatment upregulated the levels of nuclear factor κ B and nitric oxide synthase genes and elevated the production of reactive oxygen species and nitric oxide. Unlike AmB, lupeol-treated infected animals did not show any toxicity. These findings are promising and indicate that lupeol can serve as a prototype drug for the cure of VL.

Keywords

LupeolTh1 cytokinesNF-κB, iNOSsub GO/G1phase, visceral leishmaniasis
Type
Research Article
Information
Parasitology , Volume 146 , Issue 11 , September 2019 , pp. 1440 - 1450
Check for updates
Copyright
Copyright © Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Postal address: Parasitology laboratory, Department of Zoology, Panjab University, Chandigarh, India

References

Artis, D, Speirs, K, Joyce, K, Goldschmidt, M, Caamano, J, Hunter, CA and Scott, P (2003) NF-κB1 is required for optimal CD4+ Th1 cell development and resistance to Leishmania major. The Journal of Immunology 170, 1995–2003. https://doi.org/10.4049/jimmunol.170.4.1995.Google Scholar
Bacellar, O and Carvalho, E (2005) Imunopatogênese da leishmaniose visceral. Gazeta Medica da Bahia 75, 24–34.Google Scholar
Banerjee, A, De, M and Ali, N (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. The Journal of Immunology 181, 1386–1398. https://doi.org/10.4049/jimmunol.181.2.1386.Google Scholar
Bruce, J and Wong, I (2001) Parenteral drug administration errors by nursing staff on an acute medical admissions ward during day duty. Drug Safety 24, 855–862.Google Scholar
Chattopadhyay, A and Jafurulla, M (2011) A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochemical and Biophysical Research Communications 416, 7–12. https://doi.org/10.1016/j.bbrc.2011.11.023.Google Scholar
Chawla, B, Jhingran, A, Panigrahi, A, Stuart, KD and Madhubala, R (2011) Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin – susceptible – resistant Leishmania donovani. PLoS ONE 6, e26660.Google Scholar
Corpas-Lopez, V, Morillas-Marquez, F, Navarro-Moll, MC, Merino-Espinosa, G, Diaz-Saez, V and Martin-Sanchez, J (2015) (−)-α-Bisabolol, a promising oral compound for the treatment of visceral leishmaniasis. Journal of Natural Products 78, 1202–1207.Google Scholar
Croft, SL, Sundar, S and Fairlamb, AH (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19, 111–126. https://doi.org/10.1128/CMR.19.1.111-126.2006.Google Scholar
Das, VN, Ranjan, A, Sinha, AN, Verma, N, Lal, CS, Gupta, AK, Siddiqui, NA and Kar, SK (2001) A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. The Journal of the Association of Physicians of India 49, 609–613.Google Scholar
Das, R, Roy, A, Dutta, N and Majumder, HK (2008) Reactive oxygen species and imbalance of calcium homeostasis contributes to curcumin induced programmed cell death in Leishmania donovani. Apoptosis 13, 867–882. https://doi.org/10.1007/s10495-008-0224-7.Google Scholar
Das, A, Jawed, JJ, Das, MC, Sandhu, P, De, UC, Dinda, B, Akhter, Y and Bhattacharjee, S (2017) Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa. International Journal of Antimicrobial Agents 50, 512–522. https://doi.org/10.1016/j.ijantimicag.2017.04.022.Google Scholar
Duarte, MC, Tavares, GS, Valadares, DG, Lage, DP, Ribeiro, TG, Lage, LM, Rodrigues, MR, Faraco, AA, Soto, M, da Silva, ES and Fumagalli, MA (2016) Antileishmanial activity and mechanism of action from a purified fraction of Zingiber officinalis Roscoe against Leishmania amazonensis. Experimental Parasitology 166, 21–28. https://doi.org/10.1016/j.exppara.2016.03.026.Google Scholar
Gupta, A, Khajuria, A, Singh, J, Bedi, KL, Satti, NK, Dutt, P, Suri, KA, Suri, OP and Qazi, GN (2006) Immunomodulatory activity of biopolymeric fraction RLJ-NE-205 from Picrorhiza kurroa. International Immunopharmacology 6, 1543–1549. https://doi.org/10.1016/j.intimp.2006.05.002.Google Scholar
Han, N and Bakovic, M (2015) Biologically active triterpenoids and their cardioprotective and anti-inflammatory effects. Journal of Bioanalysis and Biomedicine S12, 005. https://doi.org/10.4172/1948-593X.S12-005.Google Scholar
Hong, DS, Kurzrock, R, Supko, JG, He, X, Naing, A, Wheler, J, Lawrence, D, Eder, JP, Meyer, CJ, Ferguson, DA and Mier, J (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical Cancer Research 18, 3396–3406.Google Scholar
Horta, MF, Mendes, BP, Roma, EH, Noronha, FS, Macedo, JP, Oliveira, LS, Duarte, MM and Vieira, LQ (2012) Reactive oxygen species and nitric oxide in cutaneous leishmaniasis. Journal of Parasitology Research 2012, 1–11. http://dx.doi.org/10.1155/2012/203818.Google Scholar
Hossain, F, Ghosh, P, Khan, MA, Duthie, MS, Vallur, AC, Picone, A, Howard, RF, Reed, SG and Mondal, D (2017) Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of visceral leishmaniasis patients and the monitoring of their response to treatment. PLoS ONE 12, e0185606. https://doi.org/10.1371/journal.pone.0185606.Google Scholar
Jesus, JA, Fragoso, TN, Yamamoto, ES, Laurenti, MD, Silva, MS, Ferreira, AF, Lago, JH, Gomes, GS and Passero, LFD (2017) Therapeutic effect of ursolic acid in experimental visceral leishmaniasis. International Journal for Parasitology Drugs and Drug Resistance 7, 1–11. https://doi.org/10.1016/j.ijpddr.2016.12.002.Google Scholar
Jiménez-Arellanes, A, Luna-Herrera, J, Cornejo-Garrido, J, López-García, S, Castro-Mussot, ME, Meckes-Fischer, M, Mata-Espinosa, D, Marquina, B, Torres, J and Hernández-Pando, R (2013) Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment. BMC Complementary and Alternative Medicine 13, 258.Google Scholar
Kar, S, Ukil, A and Das, PK (2011) Cystatin cures visceral leishmaniasis by NF-κB-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway. European Journal of Immunology 41, 116–127. https://doi.org/10.1002/eji.201040533.Google Scholar
Karimi, N, Ghanbarzadeh, B, Hamishehkar, H, Pezeshki, A, Mostafayi, H and Gholian, MM (2015) Phytosome as novel delivery system for nutraceutical materials. International Journal of Current Microbiology and Applied Sciences 4, 152–159.Google Scholar
Kesarwani, K and Gupta, R (2013) Bioavailability enhancers of herbal origin: an overview. Asian Pacific journal of tropical biomedicine 3, 253–266. https://doi.org/10.1016/S2221-1691(13)60060-X.Google Scholar
Kyriazis, ID, Koutsoni, OS, Aligiannis, N, Karampetsou, K, Skaltsounis, AL and Dotsika, E (2016) The leishmanicidal activity of oleuropein is selectively regulated through inflammation-and oxidative stress-related genes. Parasites and Vectors 9, 441. https://doi.org/10.1186/s13071-016-1701-4.Google Scholar
Livak, KJ and Schmittgen, TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 − ΔΔCT method. Methods 25, 402–408. https://doi.org/10.1006/meth.2001.1262.Google Scholar
Mallick, S, Dutta, A, Chaudhuri, A, Mukherjee, D, Dey, S, Halder, S, Ghosh, J, Mukherjee, D, Sultana, SS, Biswas, G and Lai, TK (2016) Successful therapy of murine visceral leishmaniasis with astrakurkurone, a triterpene isolated from mushroom Astraeus hygrometricus, involves the induction of protective cell mediated immunity and TLR9. Antimicrobial Agents and Chemotherapy 60, 2696–2708, AAC-01943.Google Scholar
Manoharan, S, Palanimuthu, D, Baskaran, N and Silvan, S (2012) Modulating effect of lupeol on the expression pattern of apoptotic markers in 7, 12-dimethylbenz (a) anthracene induced oral carcinogenesis. Asian Pacific Journal of Cancer Prevention 13, 5753–5757.Google Scholar
Marcusso Orsini, T, Kawakami, NY, Panis, C, Fortes dos Santos Thomazelli, AP, Tomiotto-Pellissier, F, Cataneo, AH, Kian, D, Megumi Yamauchi, L, Junior, G, Florencio, S and de França Lopes, LG (2016) Antileishmanial activity and inducible nitric oxide synthase activation by RuNO complex. Mediators of Inflammation 2016, 1–10. http://dx.doi.org/10.1155/2016/2631625.Google Scholar
Melo, GD, Goyard, S, Fiette, L, Boissonnas, A, Combadiere, C, Machado, GF, Minoprio, P and Lang, T (2017) Unveiling cerebral leishmaniasis: parasites and brain inflammation in Leishmania donovani infected mice. Scientific reports 7, 8454.Google Scholar
Misra, P, Sashidhara, KV, Singh, SP, Kumar, A, Gupta, R, Chaudhaery, SS, Gupta, SS, Majumder, HK, Saxena, AK and Dube, A (2010) 16α-Hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. British Journal of Pharmacology 159, 1143–1150.Google Scholar
Mukherjee, D, Singh, CB, Dey, S, Mandal, S, Ghosh, J, Mallick, S, Hussain, A, Swapana, N, Ross, SA and Pal, C (2016) Induction of apoptosis by zerumbone isolated from Zingiber zerumbet (L.) Smith in protozoan parasite Leishmania donovani due to oxidative stress. Brazilian Journal of Infectious Diseases 20, 48–55.Google Scholar
Nagle, AS, Khare, S, Kumar, AB, Supek, F, Buchynskyy, A, Mathison, CJ, Chennamaneni, NK, Pendem, N, Buckner, FS, Gelb, MH and Molteni, V (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chemical Reviews 114, 11305–11347.Google Scholar
Oliveira, WN, Ribeiro, LE, Schrieffer, A, Machado, P, Carvalho, EM and Bacellar, O (2014) The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine 66, 127–132.Google Scholar
Paik, D, Das, P, Naskar, K, Pramanik, PK and Chakraborti, T (2016) Protective inflammatory response against visceral leishmaniasis with potato tuber extract: a new approach of successful therapy. Biomedicine and Pharmacotherapy 83, 1295–1302. https://doi.org/10.1016/j.biopha.2016.08.046.Google Scholar
Pearse, AGE (1968) Histochemistry: Theoretical and Applied. London: J.A. Churchill Ltd.Google Scholar
Pérez-Victoria, JM, Bavchvarov, BI, Torrecillas, IR, Martínez-García, M, López-Martín, C, Campillo, M, Castanys, S and Gamarro, F (2011) Sitamaquine overcomes the ABC-mediated resistance to Miltefosine and antimony in Leishmania. Antimicrobial Agents and Chemotherapy 50, 3838–3844, AAC-00065.Google Scholar
Peruhype-Magalhães, V, Martins-Filho, ODA, Prata, A, Silva LDe, A, Rabello, A, Teixeira-Carvalho, A, Figueiredo, RM, Guimarães-Carvalho, SF, Ferrari, TCDA and Correa-Oliveira, R (2005) Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scandinavian Journal of Immunology 62, 487–495.Google Scholar
Piscopo, TV and Mallia Azzopardi, C (2007) Leishmaniasis. Postgraduate Medical Journal 83, 649–657.Google Scholar
Rao, RR, Mahajan, RC and Ganguly, NK (1984) Modified media for in vitro cultivation of Leishmania promastigotes, a comparative study. PGIMER Bulletin 18, 125–128.Google Scholar
Rodrigues, APD, Farias, LHS, Carvalho, ASC, Santos, AS, do Nascimento, JLM and Silva, EO (2014) A novel function for kojic acid, a secondary metabolite from Aspergillus fungi, as antileishmanial agent. PLoS ONE 9, e91259. https://doi.org/10.1371/journal.pone.0091259.Google Scholar
Salim, T, Sershen, CL and May, EE (2016) Investigating the role of TNF-α and IFN-γ activation on the dynamics of iNOS gene expression in LPS stimulated macrophages. PLoS ONE 11, e0153289.Google Scholar
Sambrook, JF, Fritsch, EF and Maniatis, T (1989) Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor.Google Scholar
Sanchez-Burgos, JA, Ramirez-Mares, MV, Gallegos-Infante, JA, Gonzalez-Laredo, RF, Moreno-Jimenez, MR, Chairez-Ramirez, MH, Medina-Torres, L and Rocha-Guzman, NE (2015) Isolation of lupeol from white oak leaves and its anti-inflammatory activity. Industrial Crops and Products 77, 827–832. https://doi.org/10.1016/j.indcrop.2015.09.056.Google Scholar
Sankaran, M and Jayasri, G (2017) Lupeol: an ubiquitous compound for multiple ailments. Journal of Applied Research 3, 966–976.Google Scholar
Siddique, HR and Saleem, M (2011) Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sciences 88, 285–293. https://doi.org/10.1016/j.lfs.2010.11.020.Google Scholar
Singh, OP, Singh, B, Chakravarty, J and Sundar, S (2016) Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infectious Diseases of Poverty 5, 19. https://doi.org/10.1186/s40249-016-0112-2.Google Scholar
Strober, W (2001) Trypan blue exclusion test of cell viability. Current Protocols in Immunology 21, A.3B.1–A.3B.2. https://doi.org/10.1002/0471142735.ima03bs21.Google Scholar
Sundar, S and Chakravarty, J (2015) An update on pharmacotherapy for leishmaniasis. Expert Opinion on Pharmacotherapy 16, 237–252.Google Scholar
Sundar, S, Singh, A, Rai, M, Prajapati, VK, Singh, AK, Ostyn, B, Boelaert, M, Dujardin, JC and Chakravarty, J (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clinical Infectious Diseases 55, 543–550.Google Scholar
Sunitha, S, Nagaraj, M and Varalakshmi, P (2001) Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium-induced hepatotoxicity in rats. Fitoterapia 72, 516–523.Google Scholar
Tajebe, F, Getahun, M, Adem, E, Hailu, A, Lemma, M, Fikre, H, Raynes, J, Tamiru, A, Mulugeta, Z, Diro, E and Toulza, F (2017) Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites. PLoS Neglected Tropical Diseases 11, e0005727. https://doi.org/10.1371/journal.pntd.0005727.Google Scholar
Tsagozis, P, Karagouni, E and Dotsika, E (2003) CD8+ t cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunology 25, 569–579. https://doi.org/10.1111/j.0141-9838.2004.00672.x.Google Scholar
Turner, PV, Brabb, T, Pekow, C and Vasbinder, MA (2011) Administration of substances to laboratory animals: routes of administration and factors to consider. Journal of the American Association for Laboratory Animal Science 50, 600–613.Google Scholar
Wal, A, Srivastava, RS, Wal, P, Rai, A and Sharma, S (2015) Lupeol as a magical drug. Pharmaceutical and Biological Evaluations 2, 142–151.Google Scholar
Wu, XT, Liu, JQ, Lu, XT, Chen, FX, Zhou, ZH, Wang, T, Zhu, SP and Fei, SJ (2013) The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells. International Immunopharmacology 16, 332–340. http://dx.doi.org/10.1016/j.intimp.2013.04.017.Google Scholar
Zakraoui, O, Marcinkiewicz, C, Aloui, Z, Othman, H, Grepin, R, Haoues, M, Essafi, M, Srairi-Abid, N, Gasmi, A, Karoui, H and Pages, G (2017) Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression. Molecular Carcinogenesis 56, 18–35. https://doi.org/10.1002/mc.22470.Google Scholar